Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2013 | ReVision Optics | Equity | 15M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 1/2014 | PowerVision | Series D | 0 |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 2/2008 | InSound Medical | Series E | 11M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 1/2009 | Acclarent | Venture Round | 26M |
| 10/2007 | Optherion | Series A | 37M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2009 | ImaCor | Series A | 0 |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 2/2016 | Cala Health | Series B | 0 |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 4/2010 | Biocartis | Series B | 40M |
| 4/2002 | Replidyne | Series A | 13M |
| 9/2014 | Biocartis | Series F | 0 |
| 1/2011 | 23andMe | Series C | 9M |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 1/2012 | PowerVision | Series C | 12.5M |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 6/2001 | NitroMed | Series E | 0 |
| 9/2004 | Vascular Architects | Series E | 0 |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 7/2013 | CVRx | Series F | 0 |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 5/2007 | CVRx | Series D | 65M |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 11/2009 | Celladon | Series C | 21.8M |
| 2/2012 | Celladon | Venture Round | 43M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 12/2012 | Biocartis | Series D | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 3/2011 | Astute Medical | Series B | 13M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 9/2009 | NovoCure | Venture Round | - |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 5/2012 | Mitralign | Series D | 0 |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | Neotract | Series B | 28.1M |
| 10/2010 | Intio | Series B | 8.1M |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 3/2017 | Grail | Series B | 0 |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2012 | Pronota | Series C | 4.8M |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 1/2003 | Vascular Architects | Series D | 0 |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 11/2003 | CardioMEMS | Series B | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 7/2000 | Lumenos | Series B | 34M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2005 | Ilypsa | Series B | 36M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 11/2010 | Syntaxin | Series C | 29M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 12/2007 | Mitralign | Series C | 0 |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 7/2008 | CVRx | Series E | 0 |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 9/2002 | CellGate | Series D | 10M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 3/2004 | BioRexis | Series B | 30M |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 11/2013 | Biocartis | Series E | 0 |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 6/2006 | Tengion | Series B | 50M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 10/2007 | Tengion | Series C | 33M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 1/2015 | Willow | Series A | 15M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 8/2005 | Tengion | Series A | 39M |
| 10/2013 | Merus | Series B | 42.2M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 11/2004 | Corthera | Series B | 15M |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 3/2013 | Nevro | Series C | 0 |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 7/2004 | Accumetrics | Series B | 0 |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 11/2014 | La Lumiere | Series B | 20M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
